Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

NCT02075515 PHASE3 COMPLETED Results posted

The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE3
Status	COMPLETED
Enrolment	651
Start date	Wed Aug 13 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Apr 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Herpes Zoster
• Herpes Zoster Vaccine

Interventions

• Herpes Zoster vaccine (GSK 1437173A)

Countries

Belgium, Canada, United States